Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.69 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.63 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.63 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.63 |
| ▸ | SCN4A | P35499 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252800 | 1.00 | TACR1 (0.69) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL30715499 | 1.00 | TACR1 (0.69) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL16321476 | 0.96 | TACR1 (0.70) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL18580091 | 0.96 | TACR1 (0.70) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4988525 | 0.96 | TACR1 (0.70) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL22050521 | 0.87 | TACR1 (0.64) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL21995083 | 0.87 | TACR1 (0.64) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4985457 | 0.87 | TACR1 (0.76) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL21994971 | 0.86 | TACR1 (0.62) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL22457178 | 0.86 | TACR1 (0.62) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| EP-3886987-B1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-11-15 | — | — | EP | disclosed |
| US-11492361-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20220119417-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3886987-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-10-06 | — | — | EP | disclosed |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-14 | — | — | US | disclosed |
| US-10870663-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| WO-2020110056-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
| WO-2012001418-A1 | MULTI-METALLIC COMPLEXES | UNIVERSITY OF WARWICK (GB) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119417-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TACR1 825/4885CACNA1F 3798/4885CACNA1D 4418/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TACR1 825/4885CACNA1F 3798/4885CACNA1D 4418/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | TACR1 825/4885CACNA1F 3798/4885CACNA1D 4418/4885 |
| US-10870663-B2 | Compounds useful in HIV therapy | CCR5, SLC11A2, CD4 | TACR1 821/4885CACNA1F 3402/4885CACNA1D 4144/4885 |
| US-11492361-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | TACR1 652/4885CACNA1F 3532/4885CACNA1D 4141/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | TACR1 821/4885CACNA1F 3402/4885CACNA1D 4144/4885 |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TACR1 652/4885CACNA1F 3532/4885CACNA1D 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.